Table showing the baseline characteristics of the Tayside Allergy and Respiratory Disease Information System (TARDIS) cohort analysis by mannose binding lectin (MBL) genotype. p Values were calculated by three-way comparisons (Kruskal-Wallis for non-parametrical data, analysis of variance for parametrical data and Χ2 test for categorical data) across all groups
| MBL deficient genotype | MBL intermediate genotype | MBL sufficient genotype | p Value | |
| N (% of study cohort) | 240 (13.4) | 586 (32.6) | 970 (54.0) | n/a |
| Average follow-up length in years (SD) | 5.44 (±2.1) | 5.34 (±2.0) | 5.43 (±2.1) | 0.9 |
| Age at diagnosis, years (SD) | 65.6 (±9.0) | 64.23 (±9.6) | 64.4 (±9.6) | 0.1 |
| Male gender (% of group) | 131 (54.6) | 308 (52.7) | 506 (52.2) | 0.8 |
| Cigarette smoking by pack years (SD) | 41.6 (±20.6) | 41.0 (±20.3) | 41.3 (±22.7) | 0.7 |
| Body mass index (SD) | 27.0 (±5.6) | 26.9 (±5.4) | 27.2 (±5.6) | 0.9 |
| FEV1 % predicted (SD) | 79.6 (±20.8) | 78.7 (±24.4) | 78.0 (±22.1) | 0.3 |
| MRC Dyspnoea Score (SD) | 2.44 (±1.0) | 2.53 (±1.0) | 2.48 (±1.0) | 0.6 |
| FEV1/FVC (SD) | 0.59 (±0.1) | 0.58 (±0.1) | 0.58 (±0.1) | 0.3 |
| Comorbidities | ||||
| Cardiovascular disease (% of group) | 24 (10.0) | 53 (9.0) | 78 (8.0) | 0.6 |
| Renal failure (% of group) | 5 (2.1) | 17 (2.9) | 19 (2.0) | 0.5 |
| Cancer (% of group) | 12 (5.0) | 29 (4.9) | 39 (4.0) | 0.6 |
| Hypertension (% of group) | 137 (57.1) | 322 (54.9) | 524 (54.0) | 0.7 |
| Diabetes (% of group) | 48 (20.0) | 105 (17.9) | 194 (20.0) | 0.6 |
| Therapies | ||||
| Inhaled corticosteroids (% of group) | 123 (51.3) | 349 (59.6) | 570 (58.8) | 0.1 |
| Long-acting muscarinic antagonist (% of group) | 67 (27.9) | 175 (29.9) | 257 (26.5) | 0.4 |
| Statins (% of group) | 71 (29.6) | 178 (30.4) | 313 (32.3) | 0.6 |